



Not for release to US wire services or distribution in the United States

Media Release

29 April 2026

Syntara announces placement of A\$8 million and share purchase plan

Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce that it has received firm commitments from existing and new institutional and sophisticated investors to raise A\$8.0 million (before costs) by way of a two-tranche institutional placement (Placement). The Company intends to conduct a non-underwritten share purchase plan to existing eligible shareholders to raise approximately A\$2.0 million (SPP) (together with the Placement, the Capital Raising or the Offer).

The Capital Raising follows the recent announcement by the Company of its positive Type C meeting outcome with US FDA, supporting the Phase 2b clinical trial design for Syntara's lead asset amsulostat in myelofibrosis (MF).

Placement proceeds will provide a cash runway to Q3 2027 and be applied to:

- Trial readouts and licensing discussions – funding five key clinical trial readouts over CY2026 and to progress current licensing discussions across the pipeline.
- Phase 2b MF study preparation – preparatory work, including protocol finalisation, CRO selection, trial site negotiations, formulation development, and clinical trial supplies.
- Patent suite – strengthening the Company's global leading pan-LOX patent suite and add potential to exploit multiple indications.
- Offer costs – funding costs associated with the Offer.

Commenting on the Capital Raising, Syntara Chief Executive Officer Gary Phillips said, *"We're very grateful for the strong support from our shareholders and new investors in this capital raising, stemming from the positive FDA review of our clinical development plan and Phase 2b protocol for amsulostat. With this injection of capital Syntara is now very well positioned to deliver data from the five clinical studies currently underway for its three pipeline programs and explore the associated commercial potential."*

The Capital Raising comprises an institutional Placement to raise A\$8.0 million to existing and new institutional and sophisticated investors and a share purchase plan to existing eligible shareholders in Australia and New Zealand to raise A\$2.0 million, both at A\$0.027 per new share (Issue Price). All shares issued under the Placement and SPP will rank equally with existing fully paid ordinary shares in Syntara as at their date of issue (New Shares).

The Issue Price under the Capital Raising represents:

- a 15.6% discount to the last closing price of Syntara's shares on the ASX on 24 April 2026 (the last trading day before the announcement of the Placement and SPP); and
- a 17.6% discount to the 5-day volume weighted average price of Syntara's shares ended 24 April 2026.

Placement

The Placement received strong support from existing and new institutional and sophisticated investors. Syntara will issue approximately 296.3 million New Shares at the Issue Price across two tranches as follows:

- Tranche 1 to raise approximately A\$6.6 million via the issue of 242,605,411 New Shares utilising Syntara's existing Placement capacity under ASX Listing Rule 7.1 (Tranche 1). Settlement of Tranche 1 is expected to occur on 6 May 2026.
- Tranche 2 to raise approximately A\$1.4 million via the issue of 53,690,885 New Shares, subject to shareholder approval to be sought at an upcoming extraordinary general meeting of Syntara to be held in June (EGM) (Tranche 2). Settlement of Tranche 2 is expected to occur on or around Mid-Late June 2026.

Canaccord Genuity (Australia) Limited (ACN 075 071 466) and Euroz Hartleys Limited (ACN 104 195 057) acted as joint lead managers and bookrunners to the Placement.

Share Purchase Plan

Existing eligible shareholders, being those whose registered address is in Australia or New Zealand that held Syntara's shares as at 5:00pm (Sydney time) on Tuesday, 28 April 2026, will be invited to participate in the SPP at the Issue Price. The SPP will provide such shareholders the opportunity to increase their holding by up to A\$30,000 without incurring any brokerage or transaction costs.

The SPP aims to raise approximately A\$2.0 million. The SPP may also be subject to a scale back of application at the absolute discretion of the Company. The full terms and conditions of the SPP (including the timetable for the SPP) will be detailed in the SPP offer booklet, which is expected to be released in mid-May by the Company. Existing eligible shareholders should consider the offer booklet in full before deciding whether to apply for SPP Shares under the SPP pursuant to the offer booklet.

Key dates for Capital Raising*

| Event | Date |
|---|-----------------------------|
| Trading Halt | Tuesday, 28 April 2026 |
| Record Date for the SPP | 5pm, Tuesday, 28 April 2026 |
| ASX Announcement / Resume Trading | Wednesday, 29 April 2026 |
| Settlement of the New Shares under Tranche 1 | Wednesday, 6 May 2026 |
| Expected date of ASX quotation of New Shares under Tranche 1 | Thursday, 7 May 2026 |
| SPP offer booklet to be distributed to existing eligible shareholders | Mid-May 2026 |
| Date of General Meeting to approve Tranche 2 | Mid-Late June 2026 |
| Expected date of ASX quotation of New Shares under Tranche 2 | Mid-Late June 2026 |

**The dates set out in the timetable above are indicative only and are subject to change without notice. Any change in the timetable does not affect the rights or obligations an investor or shareholder has as a result of accepting an allocation in the Placement or the SPP.*

#ENDS#

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

About Syntara

Syntara Limited (ABN: 75 082 811 630) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.

Lead candidate amsulostat (also known as SNT-5505 and previously as PXS-5505) is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. Amsulostat has been granted Fast Track Designation, having already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. Amsulostat has now completed a Phase 2a trial in myelofibrosis in which it was dosed as monotherapy and in combination with a JAK inhibitor. Two Phase 1c/2 studies with amsulostat in patients with a blood cancer called myelodysplastic syndrome have been initiated.

Syntara is also advancing topical pan-LOX inhibitors with SNT-9465 in a Phase 1a/b study of hypertrophic scars and continuing the ongoing collaboration with Professor Fiona

Wood and the University of Western Australia studying SNT-6302 in keloid scars. SNT-4728 is being studied in collaboration with Parkinson's UK as a best-in-class SSAO/MAO-B inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson's by reducing neuroinflammation.

Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, MASH, pulmonary fibrosis and cardiac fibrosis.

Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), which it sold in October 2023.

Syntara is listed on the Australian Securities Exchange, code SNT. The company's management and scientific discovery team are based in Sydney, Australia.

www.syntaraTX.com.au.

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

SOURCE:

Syntara Limited (ASX: SNT),
Sydney, Australia
(ABN: 75 082 811 630)

AUTHORISED FOR RELEASE TO ASX BY:

Syntara Limited Disclosure Committee.

CONTACT:

Syntara investor / media relations:

Matthew Wright
NWR Communications
+61 451 896 420
matt@nwrcommunications.com.au

[JOIN THE SYNTARA MAILING LIST HERE](#)

